Pre-Market Movers: GELS' 53.6% Surge & the 20 Stocks You Need to Watch

GELS shares jumped 69.25% to $1.41 after the company reported positive preclinical results. The key data point that drove this? Its proprietary oral gel platform achieved a greater than 22% increase in the bioavailability of cannabidiol compared to an existing FDA-approved oil product. More importantly, it did this with a lower CBD concentration, showing higher peak exposure. That's the alpha leak: a specific, quantifiable improvement that directly addresses a key weakness of current cannabinoid products.

The market is pricing in a faster path to patient access. Gelteq highlighted Australia's Special Access Scheme (SAS) as a potential expedited pathway. This government program allows doctors to prescribe medicinal cannabis products without full regulatory approval, creating a clear, near-term catalyst for earlier patient access and faster market entry. The stock's tiny $8.95 million market cap means even a modest SAS launch could be a major inflection point.

This is a textbook biotech alpha play. The move isn't based on vague promises or broad market hype. It's driven by a concrete, positive clinical data point that de-risks the company's core delivery platform technology. The setup is simple: better absorption + a fast-track regulatory pathway = a potential commercial breakthrough for a company that's been down 58% over the past year. Watch for follow-through on the SAS plan and any partnership announcements.